Semaglutide (Ozempic) ELISA Assay Kit
The Semaglutide (Ozempic) ELISA Assay Kit is For Research Use Only
Size: 12 x 8 wells
Standard Range: 0 – 3000 ng/ml
Sensitivity: 50 ng/ml
Incubation Time: 4 hours 30 minutes
Sample Type: Serum and plasma
Sample Size: 100 µL
Assay Principle
The Semaglutide ELISA is a competitive immunoassay for the determination of Semaglutide. The anti-GLP-1 antibodies are coated on 96 well plate. A constant concentration of Biotinylated GLP-1 and varying concentration of unlabeled Semaglutide or sample compete for binding to anti-GLP-1 antibodies. Captured Biotinylated GLP-1 antibodies are subsequently bound by Streptavidin-HRP which produces a soluble colored product after addition of TMB substrate. The enzyme reaction is stopped by dispensing of stop solution into the wells. The optical density (OD) of the solution at 450 nm is inversely proportional to the amount of bound Semaglutide molecule present in standards or samples.
Assay Background
Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. FDA approval was received in October 2017. It can be used as both injection-type or oral-type drug.
